Novartis Q3 EPS $1.74 Beats $1.70 Estimate, Sales $11.78B Beat $11.40B Estimate
Portfolio Pulse from Benzinga Newsdesk
Novartis (NYSE:NVS) reported Q3 earnings of $1.74 per share, beating the analyst consensus estimate of $1.70 by 2.35%. This is a 10.13% increase from the same period last year. The company also reported quarterly sales of $11.78 billion, beating the analyst consensus estimate of $11.40 billion by 3.33%. However, this is a 6.08% decrease from the same period last year. Novartis also announced key innovation milestones, including positive Phase 3 data for multiple pipeline assets with blockbuster potential.
October 24, 2023 | 7:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis reported better-than-expected Q3 earnings and sales, along with positive Phase 3 data for multiple pipeline assets. However, sales decreased by 6.08% compared to the same period last year.
Novartis reported strong Q3 earnings and sales, beating analyst estimates. This is likely to have a positive impact on the stock in the short term. The positive Phase 3 data for multiple pipeline assets also bodes well for the company's future growth. However, the decrease in sales compared to the same period last year could be a concern for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100